Abstract:Abstract DNA hypomethylation, a process of losing methyl marks, may play an important role in cancer, especially through activating genes that promote cancer metastasis, the deadly aspect of cancer. We previously delineated using whole genome promoter methylation microarrays the landscape of hypomethylation in hepatocellular carcinoma which is one of the most common cancers worldwide. Our studies revealed that 50% of differentially methylated promoters in tumors are hypomethylated compared to adjacent normal tissue. In the present studies, using liver cancer cell lines as a model system, we evaluated the importance of the identified hypomethylated genes in liver cancer development and progression. We tested whether the hypomethylation observed in liver cancer is driven by MBD2, a protein reported previously to be implicated in DNA demethylation, which we found to be overexpressed in liver cancer patients. Following siRNA MBD2 depletion in HepG2 hepatocellular carcinoma cell line, we used methylated DNA immunoprecipitation, chromatin immunoprecipitation (ChIP) and 60K custom microarrays covering 12K bp upstream and 10K bp downstream of transcription start site to determine methylation and MBD2 binding in 300 top genes hypomethylated and/or induced in liver cancer patients and/or HepG2 cells. The array data were validated by quantitative ChIP and/or pyrosequencing. For functional analyses, we used siRNA transfection, soft agar and invasion assays. We discovered MBD2 binding peaks in 172 genes out of 300, mainly within their promoter regions. Using bioinformatic tools, we identified MBD2 binding motif and established putative transcription factors recognizing this sequence which may play a key role in recruiting MBD2 to target genes. 41% of those genes were hypermethylated in HepG2 cells after MBD2 depletion in a fragment corresponding to MBD2 binding site. In addition, expression analysis for some of the genes showed attenuation. In HepG2 cells, we depleted expression of several of the genes hypomethylated in cancer and regulated by MBD2 using siRNA and demonstrated a decrease in cell growth and invasive capacities. Our results establish a role for MBD2 in coordinating inhibition of a panel of genes involved in cancer growth and metastasis. This study was supported by a grant from the MDEIE program of the government of Quebec and the National Cancer Institute of Canada to MS. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 96. doi:10.1158/1538-7445.AM2011-96

Cancer-associated DNA hypermethylation of Polycomb targets requires DNMT3A dual recognition of histone H2AK119 ubiquitination and the nucleosome acidic patch

Cancer-associated DNA Hypermethylation of Polycomb Targets Requires DNMT3A Dual Recognition of Histone H2AK119 Ubiquitination and the Nucleosome Acidic Patch

Structure and Mechanism of DNMT3A‐mediated DNA Methylation

DNMT1 loss leads to hypermethylation of a subset of late replicating domains by DNMT3A

Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications.

DNMT3B PWWP mutations cause hypermethylation of heterochromatin

Structural Basis for DNMT3A-mediated De Novo DNA Methylation.

The Histone Mark H3K36me2 Recruits DNMT3A and Shapes the Intergenic DNA Methylation Landscape

Direct Readout of Heterochromatic H3K9me3 Regulates DNMT1-mediated Maintenance DNA Methylation.

DNA methylation shapes the Polycomb landscape during the exit from naive pluripotency

Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation

Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity

Direct ChIP-bisulfite Sequencing Reveals a Role of H3K27me3 Mediating Aberrant Hypermethylation of Promoter CpG Islands in Cancer Cells.

Comprehensive Structure-Function Characterization of DNMT3B and DNMT3A Reveals Distinctivede Novodna Methylation Mechanisms

Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms

DNA Hypermethylation As a Chemotherapy Target.

DNMT1 Reads Heterochromatic H4K20me3 to Reinforce LINE-1 DNA Methylation

Negative regulation of DNMT3A de novo DNA methylation by frequently overexpressed UHRF family proteins as a mechanism for widespread DNA hypomethylation in cancer

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

Abstract 96: the Functional Role of DNA Hypomethylation in Liver Cancer

DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation